ASX healthcare share Telix Pharmaceuticals Ltd (ASX: TLX) continued its strong run on Wednesday, rising 8% to $15.73.
Telix is now up 18% over the past month and 40% in 2026, although it remains down 36% over the past 12 months.
After a difficult year, investor sentiment has clearly improved. Here are three reasons the rally may still have further to run.
Image source: Getty Images
A powerful competitive moat
The ASX healthcare share operates in one of the most specialised areas of healthcare: radiopharmaceuticals.
These products combine radioactive isotopes with targeted therapies and diagnostics, helping doctors detect and treat diseases such as cancer with greater precision.
Importantly, this is not an industry that newcomers can easily enter.
Developing radiopharmaceuticals requires specialised expertise, manufacturing capabilities, regulatory approvals, and distribution networks that are expensive and difficult to replicate. Those barriers create a strong moat and help protect established players such as Telix from potential competitors.
As the market for precision medicine continues to expand, that competitive advantage could become increasingly valuable.
Momentum is building
The company has delivered a steady stream of positive developments in recent months.
In late February, Telix secured a key regulatory approval filing in Europe, marking an important step in expanding its commercial footprint beyond existing markets.
Momentum continued into April when the company announced that the US Food and Drug Administration had accepted its New Drug Application for TLX101-Px (Pixclara®). The acceptance represents a significant regulatory milestone and moves the product closer to potential commercialisation.
Telix also revealed a major collaboration with US biotechnology giant Regeneron Pharmaceuticals, strengthening confidence in its long-term growth strategy and pipeline potential.
Investors appear to be responding positively to the increasing number of catalysts emerging across the business.
Strong growth outlook
Telix's financial performance continues to support the bullish investment case.
In April, the company reported first-quarter 2026 group revenue of US$230 million, representing an 11% increase on the previous quarter and a 23.7% rise compared to the prior corresponding period.
Management of the ASX healthcare share continues to guide to FY2026 revenue of US$950 million to US$970 million, supported by growth in its Precision Medicine business and contributions from its radiopharmacy operations.
The company also expects to invest between US$200 million and US$240 million in research and development this year.
That investment is helping advance multiple late-stage clinical programs and upcoming regulatory milestones across the pipeline.
Management also estimates its Precision Medicine and Therapeutics portfolio addresses a potential US$32 billion market opportunity in the United States alone, highlighting the scale of the growth runway ahead.
Analysts remain bullish
Market experts continue to see significant upside.
According to TradingView data, the majority of analysts covering the ASX healthcare share rate it as a strong buy. The most optimistic price target is $31.64, implying approximately 101% upside from current levels.
Morgans is also positive on the stock, with a $24.33 price target. That suggests upside of roughly 55%.
The broker recently noted that increasing consolidation across the healthcare sector could generate additional interest in Telix shares.
